Basic Value Screen
Select holdings using PE, PB, P/FCF, and EV/EBITDA, targeting roughly one quarter of each period's original member count and no more than 20 names; when a period has over 100 members, pre-rank to the top 50 first.
AI Summary
Concentrated health care value portfolio with lower market beta, but weaker risk-adjusted returns and deeper drawdowns than the original screen.
Portfolio Snapshot
Current optimized weights for the selected default session.
| Symbol | Name | Sector | Weight | Diff |
|---|---|---|---|---|
| PFE | Pfizer Inc. | Health Care | 20.00% | +17.17 |
| ELV | Elevance Health, Inc. | Health Care | 15.49% | +13.87 |
| CI | The Cigna Group | Health Care | 14.16% | +12.68 |
| HCA | HCA Healthcare, Inc. | Health Care | 12.78% | +11.46 |
| HUM | Humana Inc. | Health Care | 6.59% | +5.95 |
| BIIB | Biogen Inc. | Health Care | 5.75% | +5.20 |
| CNC | Centene Corporation | Health Care | 5.35% | +4.85 |
| VTRS | Viatris Inc. | Health Care | 4.23% | +3.84 |
| MRNA | Moderna, Inc. | Health Care | 4.07% | +3.71 |
| SOLV | Solventum Corporation | Health Care | 2.64% | +2.43 |
| UHS | Universal Health Services, Inc. | Health Care | 2.39% | +2.21 |
| BAX | Baxter International Inc. | Health Care | 2.37% | +2.19 |
| CRL | Charles River Laboratories International, Inc. | Health Care | 2.28% | +2.11 |
| DVA | DaVita Inc. | Health Care | 1.90% | +1.77 |
Sector Exposure
- Health Care100.00%
Weight Changes
Notable position adjustments in the latest snapshot.
- PFEPfizer Inc.20.00% (+17.17)
- ELVElevance Health, Inc.15.49% (+13.87)
- CIThe Cigna Group14.16% (+12.68)
- HCAHCA Healthcare, Inc.12.78% (+11.46)
- HUMHumana Inc.6.59% (+5.95)
- BIIBBiogen Inc.5.75% (+5.20)
- CNCCentene Corporation5.35% (+4.85)
- VTRSViatris Inc.4.23% (+3.84)
- MRNAModerna, Inc.4.07% (+3.71)
- SOLVSolventum Corporation2.64% (+2.43)
- UHSUniversal Health Services, Inc.2.39% (+2.21)
- BAXBaxter International Inc.2.37% (+2.19)
- CRLCharles River Laboratories International, Inc.2.28% (+2.11)
- DVADaVita Inc.1.90% (+1.77)
Performance vs Benchmark
Strategy NAV vs benchmark — hover for exact values.
Alpha Trend
Excess return vs benchmark over time.
Drawdown Trend
Underwater curve and peak drawdown marker.
Turnover Trend
Per-period turnover with average reference.
Strategy Comparison
All four default strategies side-by-side.
| Strategy | Annualized | Alpha | Sharpe | Max DD |
|---|---|---|---|---|
| Baseline | 8.14% | -1.49% | 0.56 | -28.55% |
| Momentum Screen | 5.74% | -3.21% | 0.40 | -26.41% |
| Basic Value Screen | 6.92% | -2.01% | 0.45 | -38.07% |
| Combo Equal Screen | 10.42% | -1.06% | 0.58 | -30.54% |
vs Baseline: Annualized -1.22 · Alpha -0.52 · Sharpe -0.11
Recent Periods
Per-period performance vs benchmark.
| Period | Strategy | Benchmark | Excess | Turnover | Trades |
|---|---|---|---|---|---|
| 2025-05-31 | 2.99% | 3.75% | -0.75 | 71.05 | 19 |
| 2025-06-30 | -7.98% | 2.69% | -10.66 | 14.09 | 17 |
| 2025-07-31 | 12.54% | 2.05% | +10.49 | 11.64 | 16 |
| 2025-08-31 | 0.45% | 3.66% | -3.20 | 16.01 | 16 |
| 2025-09-30 | 0.27% | 2.05% | -1.77 | 44.32 | 16 |
| 2025-10-31 | 9.84% | 0.20% | +9.64 | 42.10 | 17 |
| 2025-11-30 | 2.17% | 0.99% | +1.18 | 54.95 | 17 |
| 2025-12-31 | 1.59% | 1.47% | +0.12 | 43.70 | 16 |
| 2026-01-31 | 4.40% | -1.35% | +5.75 | 2.72 | 15 |
| 2026-02-28 | -8.24% | -7.93% | -0.32 | 8.94 | 16 |
| 2026-03-31 | 6.05% | 9.42% | -3.37 | 16.28 | 16 |
| 2026-04-30 | 5.01% | 4.11% | +0.91 | 12.95 | 15 |
Strategy Q&A
Pre-generated questions and answers about this strategy.
- value13FChat AI
Did the value screen improve valuation exposure without hurting return quality?
The value screen reports return 6.92%, alpha -2.01%, beta 0.71, Sharpe 0.45, Sortino 0.61, and max drawdown -38.07%. Relative to baseline, annualized return changed by -1.22%, alpha changed by -0.52%, Sharpe changed by -0.11, Sortino changed by -0.13, drawdown worsened by 9.51%. The key question is whether lower valuation exposure is worth any sacrifice in growth, momentum, or quality leadership.
strategyViews.basic-value-screen.metricsstrategyViews.baseline.metrics↳ Review PE, PB, FCF yield, return quality, and momentum for the value-screen names.
- value13FChat AI
Are the selected value names mean-reversion opportunities or possible value traps?
Recent period evidence is mixed by design: the strongest period was 2025-07-31 (12.54% strategy return, 2.05% benchmark, 10.49% excess, 11.64% turnover), and the weakest was 2025-06-30 (-7.98% strategy return, 2.69% benchmark, -10.66% excess, 14.09% turnover). With turnover around 34.73% and latest changes of PFE increase to 20.00%; ELV increase to 15.49%; CI increase to 14.16%, the user should verify whether each selected name has improving fundamentals, not just a low multiple.
strategyViews.basic-value-screen.periodPerformancestrategyViews.basic-value-screen.latestChanges↳ Identify whether each selected value name has improving fundamentals or only a low valuation multiple.
- value13FChat AI
Did the value screen reduce concentration or simply rotate into another concentrated bet?
The selected value book has top 5 69.02%, top 10 91.06%, top 20 100.00%, versus baseline top 5 43.85%, top 10 59.80%, top 20 80.01%. Its largest positions are PFE (Pfizer Inc.) 20.00%, ELV (Elevance Health, Inc.) 15.49%, CI (The Cigna Group) 14.16%, and HCA 12.78%, so concentration risk still needs to be reviewed even if the names look cheaper.
strategyViews.basic-value-screen.concentrationstrategyViews.baseline.concentration↳ Compare value-screen top weights with baseline top weights and identify the largest reallocations.
Other strategies for this fund
Baseline
Track disclosed holdings with the standard reporting lag and no active reweighting.
Momentum Screen
Select holdings by historically observable momentum, targeting roughly one quarter of each period's original member count and no more than 20 names; when a period has over 100 members, pre-rank to the top 50 first.
Combo Equal Screen
Filter for large-cap, quality, and low-leverage holdings, rank by composite quality/value/size score, keep the top 20 names, and equal-weight the selected names.